4-(Oxiran-2-ylmethyl)-3-phenyl-4,5-dihydro-1,2,4-oxadiazol-5-one

Catalog No. :
ACRQMC378
CAS No. :
56493-76-6
Molecular Formula :
C11H10N2O3
Molecular Weight :
218.21

IUPAC Name:4-(oxiran-2-ylmethyl)-3-phenyl-1,2,4-oxadiazol-5(4H)-one

4-(Oxiran-2-ylmethyl)-3-phenyl-4,5-dihydro-1,2,4-oxadiazol-5-one structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$182.00Login to see priceInquiryInquiry
250mg95%$254.00Login to see priceInquiryInquiry
1g95%$606.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name4-(Oxiran-2-ylmethyl)-3-phenyl-4,5-dihydro-1,2,4-oxadiazol-5-one
IUPAC Name4-(oxiran-2-ylmethyl)-3-phenyl-1,2,4-oxadiazol-5(4H)-one
MDL No.MFCD17480403
Molecular FormulaC11H10N2O3
Molecular Weight218.21
SMILESO=C1N(CC2OC2)C(C3=CC=CC=C3)=NO1
InChI KeyQPIPAGUZVXXYBL-UHFFFAOYSA-N
Synonym4-(oxiran-2-ylmethyl)-3-phenyl-4,5-dihydro-1,2,4-oxadiazol-5-one;1,2,4-Oxadiazol-5(4H)-one, 4-(2-oxiranylmethyl)-3-phenyl-
CAS No.56493-76-6

Safety Data

Pictogram
CorrosiveHealth hazard
Signal Word
Gefahr
Hazard Statement(s)
H302-H312-H315-H319-H350
Precautionary Statement(s)
P201-P202-P210-P261-P264-P271-P280-P302+P352+P312-P305+P351+P338-P308+P313-P337+P313-P370+P378-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACRQMC378 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACRQMC378 route product structure diagram
    ACRQMC37856493-76-6
Inquiry

2. ACRQMC378 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACGCIT319 route compound structure diagram
    ACGCIT3191456-22-0 In Stock
  4. Then
  5. ACRQMC378 route product structure diagram
    ACRQMC37856493-76-6
Inquiry

Comments (0)